Navigation Links
Walking Upright Saves Humans 75 Pc More Energy Compared to Apes

Though as to exactly when humans started walking on two legs is something yet to be ascertained, scientists have nevertheless hypothesized that bipedalism evolved as a way of reducing locomotor energy costs.

In the first study to fully examine this theory among humans and adult chimpanzees, the team of scientists from Washington University in St. Louis, University of California and University of Arizona, used treadmill trials to analyze walking energetics and biomechanics for adult chimpanzees and humans.

The only other research study on chimpanzee locomotor cost, conducted in 1973, used juvenile chimpanzees, which have different locomotor mechanics and costs than adults.

The team also examined the early hominin fossil record, which they found to include predicted changes consistent with lower energy cost- longer hind legs compared to body mass and structural changes to the pelvic bone allowing for more upright walking.

Analysis of these features in early fossil hominins, coupled with analysis of bipedal walking in chimpanzees, revealed that human walking was around 75 percent less costly, in terms of energy and caloric expenditure than bipedal walking and quadrupedal knucklewalking in chimpanzees.

The energy savings could have provided early hominids with an evolutionary advantage over other apes by reducing the cost of foraging for food, said Herman Pontzer, Ph.D., assistant professor of Anthropology in Arts & Sciences at Washington University in St. Louis.

"Walking upright on two legs is a defining feature that makes us human. It distinguishes our entire lineage from all other apes," said Prof. Pontzer.

The study "Chimpanzee Locomotor Energetics and the Origin of Human Bipedalism" appears in online in the July 17 issue of the Proceedings of the National Academy of Sciences




'"/>




Page: 1

Related medicine news :

1. Brisk Walking lowers memory loss in women
2. Cobblestone Walking May Be The Key For Healthy Living.
3. Peripheral Artery Disease Can Be Delayed By Walking
4. Gardening, Walking and moderate drinking reduce risk of dementia
5. Hi-tech Walking Stick Developed For Visually Impaired
6. Fight Nicotine With Brisk Walking
7. Electronic Nerve Stimulator Enables Walking
8. Targeted Initiatives may Help Promote Walking in People
9. New Device for Stroke Patients Improves Walking
10. Walking Really is the Best Way to Keep Healthy
11. Walking is Vital to Keep Yourself Fit
Post Your Comments:
(Date:10/13/2008)...ER WITH THE VIPER RESPONDER LE SPECIAL ...VISTA, Calif., Oct. 13 /PRNewswire-FirstCall/ -- D...DEI Holdings Inc. (Nasdaq: DEIX ), has joined,the... of Responder LE,Special Edition 2-Way Vehicle Sec...g Susan G. Komen for the Cure. For each pink Respo...
(Date:10/13/2008)...han Alzheimer,s patients, healthy controls , ...nson,s disease patients are more likely than healt...D deficiency, say researchers from the Emory Unive...pared vitamin D levels in 100 Parkinson,s patients...atched for age and other factors. , "Significan...
(Date:10/13/2008)...IH funding advances study Study needed becau...LIS, Oct. 13 /PRNewswire/ -- Advanced Circulatory ... ) announced today that it has received,an additio...itutes of,Health (NIH) to continue a study testing...rience cardiac arrest outside a hospital. Parts of...
(Date:10/13/2008)...re/ -- The National Coalition for,Quality Colorect...rns over,the National CT Colonography Study publis...icine. The evidence must be closely evaluated, and...s not without significant,potential risks. The Nat...remains the "Gold Standard" for colorectal cancer ...
Breaking Medicine News(10 mins):Health News:Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month 2Health News:Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month 3Health News:Parkinson's Patients More Prone to Vitamin D Deficiency 2Health News:3 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3
...or for cardiovascular diseases.A potbelly indicate...f the rest of the body is skinny as a beanpole. T...isk is the relationship of waist size to the hips,...icts an increased risk of heart attack. The study ...
...immings of cloned pig’s bacon, a jar of cloned cow...er; ‘Frankenstein foods’, as some// refer to it. ...stration (FDA) of US is getting ready to pass a bi...animal products. “We based our decision on lookin...
...'s 2002 Gay Pride, San Francisco Department of Pub...arize syphilis testing. In the above said campaig...roduced to Gayville, encouraging the many hundreds...hered there to get themselves tested for the big-S...
... a weight reduction pill, which works better and f... risk of heart disease, diabetes and cancer. Exis...ve to 10 percent when taken for a year. But men a...e new pill developed by Californian biopharmaceuti...
Other Medicine News:Health News:Pot Belly Is A Better Risk Predictor Of Heart Attack Than BMI 2Health News:Clones On the Menu 2
(Date:10/10/2008)...INGTON and MENLO PARK, Calif., Oct. 10 /PRNewswire...announced that it plans to present,long-term follo...rials next,week at the Cardiovascular Research Fou...diovascular Therapeutics (TCT) meeting in Washingt... studies designed to investigate,the safety and ef...
(Date:10/10/2008)...SANTON, Calif., Oct. 10 /- TriReme Me...authorized to affix the CE (Conformite,Europeenne)...M) Coronary,Stent System, a unique main vessel ste...ronary bifurcations., Representing the next gener...tem has potential use in a quarter of the 2.2 mill...
(Date:10/9/2008)...pps Translational Science Institute, Navigenics, A...lth study, SAN DIEGO, Oct. 9 /- A co...eaders have joined forces in a first-of-its-kind,r...ersonal genetic testing,on people who choose to re...risk for developing certain diseases., Sponsored ...
(Date:10/8/2008)...ona Heart Institute Pioneers Research That May Off...ct. 8 /- Nationally, over 3,000 peopl...ease on life. Sadly, only half,of those will recei...na,Heart Institute (AHI) is paving the way for how..., To view the Multimedia News Release, go to:, ht...
Breaking Medicine Technology:XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Patient Safety Technologies Closes on 242 325 Million in Equity Financing 25845 1Patient Safety Technologies Closes on 242 325 Million in Equity Financing 25845 2Replidyne Announces Restructuring of Operations 25843 1Replidyne Announces Restructuring of Operations 25843 2VaxGen Provides Financial Update Following the Filing of Its 10 Q for Second Quarter With SEC 3B Results Include 248 5 Million Charge in Respect of M 25840 1VaxGen Provides Financial Update Following the Filing of Its 10 Q for Second Quarter With SEC 3B Results Include 248 5 Million Charge in Respect of M 25840 2VaxGen Provides Financial Update Following the Filing of Its 10 Q for Second Quarter With SEC 3B Results Include 248 5 Million Charge in Respect of M 25840 3New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 1New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 2New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 3New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 4New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 5New England Journal of Medicine Publishes Phase III Results of VELCADE 28R 29 28Bortezomib 29 for Injection in Previously Untreated Multiple Myeloma 2902 6
...23, 2007 /PRNewswire-FirstCall/ -- Shire plc,annou...l system),the first and only non-oral medication ...ctivity Disorder (ADHD) in children aged 6,to 12 y...control,and tolerability, according to results of ...can Psychiatric Association (APA),annual meeting i...
...--(BUSINESS WIRE)--May 23, 2007 - Synta,Pharmaceut...mpany,focused on discovering, developing, and comm...edical conditions, today announced,that survival a...trial in metastatic melanoma of the Company,s lead...ted at the annual meeting of the,American Society ...
Other Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 2Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 3
... Volk Area Centralis® is excellent for critica...ization and changes from macular degeneration, ret...proliferative diabetic retinopathy and other retin...nt of these conditions providing excellent magnifi...
... original 130° QuadrAspheric lens has grown in...preferred wide field fundus laser lens. Its sleek ...age over competitive wide field lenses for periphe...ease of use. This lens is excellent for small pupi...
The Digital Wide Field Lens combines exceptional wide field views and high magnification. The enhanced double aspheric design and multi-layer coating provide high resolution stereo views of the retin
...ks Super VitreoFundus® provides ultra wide-fie... quick and comprehensive fundus exams at the slit ... a wide field of view through small pupils without...all pupil lenses. Delivering an incredible 124°...
Medicine Products: